A patient taking levothyroxine 50 µg daily has a thyroid‑stimulating hormone (TSH) level of 5.6 mIU/L (reference range 0.4–4.5). What is the appropriate next step in management?

Increase Levothyroxine Dose to 75 µg Daily

For a patient taking levothyroxine 50 µg daily with a TSH of 5.6 mIU/L (reference range 0.4–4.5), the appropriate next step is to increase the levothyroxine dose by 12.5–25 µg, bringing the daily dose to 62.5–75 µg, and recheck TSH in 6–8 weeks. 1

Rationale for Dose Adjustment

• The current TSH of 5.6 mIU/L indicates inadequate thyroid hormone replacement in a patient already on levothyroxine therapy, requiring dose escalation to normalize TSH into the reference range of 0.5–4.5 mIU/L 1

• For patients with TSH 4.5–10 mIU/L who are already on levothyroxine, dose adjustment is reasonable to normalize TSH into the reference range, even though this represents subclinical hypothyroidism 1

• The patient's TSH elevation while on treatment suggests the current 50 µg dose is insufficient to meet their thyroid hormone requirements, and failure to adjust risks persistent hypothyroid symptoms, adverse cardiovascular effects, and abnormal lipid metabolism 1

Specific Dose Adjustment Protocol

• Increase levothyroxine by 12.5–25 µg based on the patient's current dose and clinical characteristics 1

• For this patient on 50 µg daily, a reasonable increase would be to 62.5 µg or 75 µg daily (representing a 25–50% dose increase), which is appropriate for the degree of TSH elevation observed 1, 2

• Larger adjustments may lead to overtreatment and should be avoided, especially in elderly patients or those with cardiac disease 1

Monitoring Strategy

• Recheck TSH and free T4 in 6–8 weeks after dose adjustment, as this represents the time needed to reach steady state with the new levothyroxine dose 1

• Target TSH should be within the reference range (0.5–4.5 mIU/L) with normal free T4 levels 1

• Once adequately treated, repeat testing every 6–12 months or if symptoms change 1

Special Considerations Based on Patient Characteristics

For Patients <70 Years Without Cardiac Disease

• More aggressive titration may be appropriate, using 25 µg increments to reach target TSH more rapidly 1

• The full replacement dose is approximately 1.6 mcg/kg/day, which can guide the ultimate target dose 1, 2

For Patients >70 Years or With Cardiac Disease

• Use smaller increments (12.5 µg) to avoid potential cardiac complications during dose adjustment 1

• Titrate more slowly, every 6–8 weeks, to prevent unmasking cardiac ischemia or precipitating arrhythmias 1, 2

Common Pitfalls to Avoid

• Avoid excessive dose increases that could lead to iatrogenic hyperthyroidism, which increases risk for osteoporosis, fractures, abnormal cardiac output, and ventricular hypertrophy 1

• Do not recheck TSH too soon after dose adjustment (before 6–8 weeks), as steady state has not been reached and results will be misleading 1

• Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, highlighting the importance of careful monitoring after dose increases 1

• Never assume the patient is non-adherent without first confirming medication compliance, as malabsorption, drug interactions, or increased thyroid hormone requirements may explain inadequate TSH control 2, 3

Evidence Quality

• The recommendation for dose adjustment at TSH 4.5–10 mIU/L in patients already on levothyroxine is supported by fair-quality evidence from expert panels, reflecting that treatment is reasonable to normalize TSH and potentially improve symptoms 1

• For patients with TSH >10 mIU/L, treatment is more strongly recommended regardless of symptoms, as this level carries approximately 5% annual risk of progression to overt hypothyroidism 1